NICE has issued its final appraisal decision recommending reimbursement of Lenvima for the treatment of progressive, locally advanced or metastatic, differentiated thyroid carcinoma...
Original Article: NICE approves Lenvima for differentiated thyroid cancer
NEXT ARTICLE